BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... BioNTech is also exploring combinations with antibody-drug ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

In the trial, patients with non-small-cell lung cancer (NSCLC) were treated with either ivonescimab or the drug that's the ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Natalie Willacy has so far poured $40,000 of her super into self-funding her own immunotherapy treatment with the ...